Further studies evaluating pharmacologic PPARγ agonists such as rosiglitazone, particularly in metabolically vulnerable breast cancer subtypes, are warranted to test its translational relevance in breast cancer from our findings, as was done in a single, small study which aimed to examine tumor biomarkers rather than outcomes (Yee et al., 2007). This evidence concerns the gene PPARG and breast cancer.